Publications by authors named "Ramon Schweizer"
Clin Cancer Res
June 2024
Article Synopsis
- Abemaciclib, a CDK4/6 inhibitor, has shown promise in treating metastatic castration-resistant prostate cancer (mCRPC), potentially shifting treatment approaches similar to its use in breast cancer.
- In a study involving 44 patients with mCRPC who had previously undergone multiple treatments, the primary goal was to report the objective response rate (ORR), which was found to be 6.8%, with a disease control rate of 45.5%.
- The treatment was generally well tolerated, with manageable side effects, and provided preliminary evidence supporting CDK4/6 as a therapeutic target in prostate cancer.
